Stay updated on Efficacy Safety Tislelizumab Fruquintinib Combo Clinical Trial
Sign up to get notified when there's something new on the Efficacy Safety Tislelizumab Fruquintinib Combo Clinical Trial page.

Latest updates to the Efficacy Safety Tislelizumab Fruquintinib Combo Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check15 days agoNo Change Detected
- Check23 days agoChange DetectedThe webpage has undergone significant changes, including the removal of detailed descriptions of a Phase 2 study involving tislelizumab and fruquintinib, while adding new identifiers and collaborators related to advanced solid tumors.SummaryDifference17%
- Check30 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check37 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check44 days agoChange DetectedThe web page has been updated to reflect the results of a Phase 2 study on the efficacy and safety of tislelizumab in combination with fruquintinib for advanced cancers, with specific details on study design, participant criteria, and outcome measures now included. Additionally, the results reporting dates have been updated.SummaryDifference84%
- Check66 days agoChange DetectedThe page has removed a notice about heavy traffic affecting certain services and the absence of posted results, while adding a confirmation that results have been submitted.SummaryDifference2%
Stay in the know with updates to Efficacy Safety Tislelizumab Fruquintinib Combo Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Efficacy Safety Tislelizumab Fruquintinib Combo Clinical Trial page.